Latest news and press releases about Entrada Therapeutics, Inc. (TRDA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches.
Price
| Price | $6.89 |
| Market Cap | $267M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.22 |
| EV / EBITDA | -1.37 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -57.61% |
| Return on Invested Capital | -62.61% |
| Return on Assets | -55.47% |
| Gross Margin | -754.72% |
| Operating Margin | -3767.07% |
| Net Margin | -3537.73% |
Related companies: ACHV · ALLO · ARCT · AVIR · CAPR · HUMA · IMRX
Explore sector: Healthcare · Biotechnology
More sections of TRDA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks